Crispr Therapeutics AG's total assets for Q4 2024 were $2.24B, a decrease of -0.62% from the previous quarter. CRSP total liabilities were $309.95M for the fiscal quarter, a -2.06% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.